Research programme: Lentiviral gene therapeutics - Calimmune

Drug Profile

Research programme: Lentiviral gene therapeutics - Calimmune

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator Calimmune
  • Class Antianaemics; Gene therapies; Stem cell therapies
  • Mechanism of Action Gene modulators; Stem cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Research Beta-thalassaemia; Sickle cell anaemia

Most Recent Events

  • 05 Dec 2016 Calimmune in-licenses gene therapy constructs from Cincinnati Children’s Hospital Medical Center
  • 05 Dec 2016 Early research in Beta-thalassaemia in USA (Parenteral)
  • 05 Dec 2016 Early research in Sickle cell anaemia in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top